ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+7.99%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$6.86B
AUM Growth
+$6.86B
(-8.7%)
Cap. Flow
-$827M
Cap. Flow
% of AUM
-12.06%
Top 10 Holdings %
Top 10 Hldgs %
69.62%
Holding
42
New
–
Increased
10
Reduced
8
Closed
6
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$118M |
| 2 |
Vaxcyte
PCVX
|
$68.6M |
| 3 |
Krystal Biotech
KRYS
|
$34.4M |
| 4 |
Kymera Therapeutics
KYMR
|
$28.9M |
| 5 |
Dyne Therapeutics
DYN
|
$19.2M |
Top Sells
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$308M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$281M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$177M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$97.2M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$70M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $1.02B | 14.94% | 2,858,888 | – | – |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $745M | 10.86% | 4,988,888 +792,227 | +19% | +$118M |
|
3
argenx
ARGX
$43.6B
| $671M | 9.79% | 1,238,467 | – | – |
|
|
4
Krystal Biotech
KRYS
$4.27B
| $477M | 6.96% | 2,622,222 +189,222 | +8% | +$34.4M |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $431M | 6.28% | 2,029,000 -26,555 | -1% | -$5.64M |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $320M | 4.67% | 11,111,111 | – | – |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $319M | 4.65% | 2,555,555 -444,445 | -15% | -$55.5M |
|
8
Avidity Biosciences
RNA
$5.99B
| $316M | 4.6% | 6,875,000 +370,000 | +6% | +$17M |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $248M | 3.61% | 23,175,000 -4,225,000 | -15% | -$45.1M |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $223M | 3.25% | 3,050,000 +50,000 | +2% | +$3.66M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $223M | 3.25% | 5,666,666 | – | – |
|
|
12
Kymera Therapeutics
KYMR
$2.95B
| $213M | 3.11% | 4,500,000 +611,112 | +16% | +$28.9M |
|
13
Vera Therapeutics
VERA
$1.38B
| $190M | 2.78% | 4,309,590 | – | – |
|
14
Arrowhead Research
ARWR
$3.05B
| $172M | 2.51% | 8,888,888 | – | – |
|
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $143M | 2.09% | 2,038,015 -2,519,401 | -55% | -$177M |
|
16
MoonLake Immunotherapeutics
MLTX
$3.54B
| $140M | 2.04% | 2,770,100 +100 | +0% | +$5.04K |
|
|
17
Vaxcyte
PCVX
$4B
| $134M | 1.96% | 1,175,000 +600,000 | +104% | +$68.6M |
|
18
Soleno Therapeutics
SLNO
$3.6B
| $110M | 1.61% | 2,181,000 +89,334 | +4% | +$4.51M |
|
19
BioCryst Pharmaceuticals
BCRX
$1.74B
| $90.2M | 1.31% | 11,865,000 -705,000 | -6% | -$5.36M |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $74.9M | 1.09% | 3,888,437 | – | – |
|
21
Ocular Therapeutix
OCUL
$2.12B
| $70.1M | 1.02% | 8,060,000 | – | – |
|
22
Kura Oncology
KURA
$686M
| $69.2M | 1.01% | 3,541,505 | – | – |
|
23
Merus
MRUS
$4.98B
| $67.7M | 0.99% | 1,355,000 | – | – |
|
24
Tourmaline Bio
TRML
$601M
| $57.1M | 0.83% | 2,222,222 | – | – |
|
25
MannKind Corp
MNKD
$1.41B
| $55M | 0.8% | 8,750,000 -9,524 | -0.1% | -$59.9K |
|